Drug Profile
Sabarubicin - Menarini Pharmaceuticals
Alternative Names: BMS 195615; MEN-10755Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Menarini
- Class Anthracyclines; Cytostatic antibiotics
- Mechanism of Action Apoptosis stimulants; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in China (IV, Infusion)
- 06 Feb 2018 Sabarubicin is still in clinical development for Small cell lung cancer (Menarini Pharmaceuticals website, February 2018)
- 09 Sep 2015 No recent reports on development was identified - Phase-II for Solid tumours in Europe (IV)